Literature DB >> 16754797

Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity.

Daisuke Nagata1, Masao Takahashi, Kuniko Sawai, Tetsuya Tagami, Takeshi Usui, Akira Shimatsu, Yasunobu Hirata, Mitsuhide Naruse.   

Abstract

Although the proinflammatory and profibrotic actions of aldosterone (Aldo) on the vasculature have been reported, the effects and molecular mechanisms of Aldo on endothelial function are yet to be determined. We investigated how Aldo regulates endothelial NO synthase (eNOS) function in human umbilical vein endothelial cells (HUVECs). HUVECs were incubated for 16 hours with Aldo 10(-7) mol/L. The concentration of reactive oxygen species was estimated by measuring 2',7'-dichlorodihydrofluorescein diacetate chemiluminescence. Signal transduction was estimated by Western immunoblots. Real-time RT-PCR was performed to measure expression of transcripts of endogenous GTP cyclohydrolase-1 and components of reduced nicotinamide-adenine dinucleotide phosphate oxidase. To eliminate the possible effect of the glucocorticoid receptor (GR) and to emphasize the role of mineralocorticoid receptor, we used GR small interfering RNA and knocked down GR expression in several experiments. NO output was estimated by intracellular cGMP concentration. Reactive oxygen species production increased significantly in Aldo-treated HUVECs but was abolished by pretreatment with eplerenone. Transcripts of p47(phox) were increased by Aldo treatment. Vascular endothelial growth factor-induced eNOS Ser 1177 but not Akt Ser 473 phosphorylation levels were reduced significantly by pretreatment with Aldo. Pretreatment with either eplerenone or okadaic acid restored phosphorylation levels of eNOS Ser 1177 in Aldo-treated cells, suggesting that protein phosphatase 2A was upregulated by Aldo via mineralocorticoid receptor. The decrease in NO output caused by Aldo pretreatment was reversed significantly by 5,6,7,8-tetrahydrobiopterin, GTP cyclohydrolase-1 overexpression, or p47(phox) knockdown. These results suggest that Aldo inhibits eNOS function through bimodal mechanisms of 5,6,7,8-tetrahydrobiopterin deficiency and protein phosphatase 2A activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16754797     DOI: 10.1161/01.HYP.0000226054.53527.bb

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  54 in total

1.  Reactive oxygen species, NADPH oxidases, and hypertension.

Authors:  Srinivasa Raju Datla; Kathy K Griendling
Journal:  Hypertension       Date:  2010-07-19       Impact factor: 10.190

Review 2.  Is the vascular endothelium under the control of aldosterone? Facts and hypothesis.

Authors:  Hans Oberleithner
Journal:  Pflugers Arch       Date:  2007-02-07       Impact factor: 3.657

Review 3.  Effect of excessive salt intake: role of plasma sodium.

Authors:  Stefan Reuter; Eckhart Büssemaker; Martin Hausberg; Hermann Pavenstädt; Uta Hillebrand
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

4.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

Review 5.  Mineralocorticoid Receptors, Neuroinflammation and Hypertensive Encephalopathy.

Authors:  Maria Elvira Brocca; Luciana Pietranera; Edo Ronald de Kloet; Alejandro Federico De Nicola
Journal:  Cell Mol Neurobiol       Date:  2018-08-16       Impact factor: 5.046

Review 6.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

Review 7.  The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction.

Authors:  Fei Wu; Yun Lin; Qingyong Liu
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

8.  Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone.

Authors:  Erwan Heylen; An Huang; Dong Sun; Gabor Kaley
Journal:  J Cardiovasc Pharmacol       Date:  2009-12       Impact factor: 3.105

Review 9.  Direct contribution of vascular mineralocorticoid receptors to blood pressure regulation.

Authors:  Kathleen V Barrett; Amy T McCurley; Iris Z Jaffe
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-12       Impact factor: 2.557

10.  Progression of renal dysfunction in patients with cardiovascular disease.

Authors:  Yasunobu Hirata; Arihiro Kiyosue; Masao Takahashi; Hiroshi Satonaka; Daisuke Nagata; Masataka Sata; Etsu Suzuki; Ryozo Nagai
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.